首页> 外文期刊>Trials >Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol
【24h】

Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol

机译:在中药临床试验中开发用于非瓣膜性房颤的核心结果集(COS)和选择结果测量工具(OMI):研究方案

获取原文
       

摘要

An increasing number of clinical trials of traditional Chinese medicine are being conducted in the treatment of non-valvular atrial fibrillation (NVAF) in China. However, the heterogeneity of outcomes and outcome measurement instruments has produced little evidence for traditional Chinese medicine in treating NVAF because many trials cannot be included in a meta-analysis. The majority of the trials did not report endpoint outcomes, side effects or other important outcomes for patients, which makes it difficult to evaluate the efficacy and safety of traditional Chinese medicine. Therefore, it is important to develop a core outcome set (COS). Although there are two related COSs for clinical trials of atrial fibrillation, the methodology is limited, and the perspectives of Chinese experts and patients are unclear. Therefore, we will develop a COS and recommend outcome measurement instruments after finishing the COS, which can be used for clinical trials of traditional Chinese medicine in NVAF. The method of the study will include eight stages led by a national multidisciplinary Steering Committee: (1) A systematic review will be developed to identify currently reported outcomes and traditional Chinese medicine syndromes in clinical trials of NVAF, (2) Semi-structured interviews of patients will be conducted to fill gaps in potential outcomes, (3) Traditional Chinese medicine syndrome names will be identified from medical records, (4) A dataset of traditional Chinese medicine syndrome names will be developed, (5) The investigation of traditional Chinese medicine syndromes will be conducted from cross-sectional study, (6) Two rounds of Delphi surveys will be carried out, (7) A consensus meeting will be conducted to develop a COS, and (8) Recommendations of outcome measurement instruments (OMIs), which should be used in the COS, will be developed. The COS will improve the consistency of outcome reporting and reduce the reporting bias in NVAF clinical trials of traditional Chinese medicine to improve the value of traditional Chinese medicine clinical trials. This study is not a clinical trial, so it is registered in Core Outcome Measures in Effectiveness Trials Initiative (COMET). Registration number: 941 . Registered on 22 December 2016.
机译:在中国,越来越多的中药临床试验正在用于治疗非瓣膜性心房颤动(NVAF)。但是,结果和结果测量工具的异质性几乎没有为中医药治疗NVAF提供任何证据,因为荟萃分析不能包括许多试验。大多数试验未报告患者的终点结局,副作用或其他重要结局,因此难以评估中药的疗效和安全性。因此,开发核心结果集(COS)非常重要。尽管有两种相关的COS用于房颤的临床试验,但方法学有限,中国专家和患者的观点尚不清楚。因此,在完成COS之后,我们将开发COS并推荐结果测量仪器,该仪器可用于NVAF中药的临床试验。该研究方法将包括由国家多学科指导委员会领导的八个阶段:(1)将进行系统评价,以鉴定NVAF临床试验中当前报告的结果和中医证候;(2)对NAF进行半结构化访谈将对患者进行治疗以填补潜在结果的空白,(3)从病历中识别中医证候名,(4)将开发中医证候名的数据集,(5)中医调查综合症将通过横断面研究进行,(6)将进行两轮Delphi调查,(7)将召开共识会议以开发COS,(8)成果测量工具(OMI)的建议,将开发应在COS中使用的软件。 COS将改善结果报告的一致性,并减少NVAF中药临床试验中报告的偏倚,从而提高中药临床试验的价值。这项研究不是临床试验,因此已在“有效性试验计划”的“核心结果测量”计划(COMET)中进行了注册。注册编号:941。 2016年12月22日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号